The UK and US have signed a landmark bilateral deal that will maintain zero import taxes on British pharmaceutical shipments being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge ensures that tariffs on these vital exports will be held at nothing for a period of 36 months.
This agreement follows previous statements to hike tariffs on patented pharmaceutical products, with potential rates floated up to 100%.
"This arrangement between the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue balance to American-British drug exports," a release noted.
Economic Importance
Pharmaceuticals are one of the UK's biggest export categories to the United States, which is by far the biggest market for major British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of September, the UK sold medicines worth over eleven billion pounds to the US. This figure made up 17.4% of total UK exports in that span.
"This guarantee secures jobs, increases capital expenditure and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official remarked.
Key UK Commitments
The deal includes several notable pledges from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates were more than twenty percent.
Recent Tensions
This agreement comes amid a ongoing tension between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
These tensions were heightened by claims that American consumers were paying a premium for the same drugs than patients in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward US facilities.
A senior figure publicly accepted that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
